Articles

EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically. 

EMA Aims to Develop Guideline for mRNA Vaccines

The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.

Biosynth Acquires Celares for Growing Conjugate Vaccine Market

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Parenteral packaging and handling advancements receive awards.

INTERPHEX 2023 Honors Packaging Innovations

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA's approval of Leqembi paves the way for wider coverage of the drug by Medicare and establishes a process for further clinical testing and evaluation of treatments for this widespread, debilitating condition

Large Clinical Trial Supports Alzheimer Drug Full Approval

The transaction is expected to be completed by the end of 2023 where CorEvitas will become a part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.

Thermo Fisher Scientific Agrees to Acquire CorEvitas

Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Caribou Biosciences Receives $25 Million Equity Investment from Pfizer

Feliza Mirasol is the science editor for 

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Camena Bioscience Raises $10 Million to Pursue DNA Synthesis Technology

Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.

Thermo Fisher Scientific Releases Tumoroid Culture Medium Kit 

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service 

EMA, the European Commission, and HMAs are phasing out the flexible regulations put into place during the pandemic.

News